Efficacy and tolerability of second-generation antidepressants in social anxiety disorder
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
A systematic review and meta-analysis were conducted to evaluate the comparative efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Studies were identified by searching MEDLINE, Embase, The Cochrane Library, PsychLit, and the International Pharmaceutical Abstracts from January 1980 through October 2006. Comparative evidence was summarized and indirect comparisons were made using network meta-analysis. Only three head-to-head trials were identified; comparative trials found only minimal differences in efficacy between escitalopram and paroxetine, and no statistically significant differences in efficacy between extended-release venlafaxine and paroxetine. Pooled evidence from 15 placebo-controlled trials suggests that escitalopram [relative benefit (RB) 1.3; 95% confidence interval (CI) 1.2-1.5], paroxetine (RB 1.9; 95% CI 1.5-2.3), sertraline (RB 1.8; 95% CI 1.5-2.2), and venlafaxine (RB 1.7; 95% CI 1.5-1.9) all produce significantly more responders than placebo; evidence favored fluvoxamine over placebo but was not significant (RB 1.5; 95% CI 0.9-2.4). Network meta-analysis did not reveal differences in efficacy among drugs. Overall, a fair amount of evidence supports the efficacy of escitalopram, fluvoxamine, paroxetine, sertraline, and venlafaxine in social anxiety disorder. The drugs do not differ in efficacy, although their adverse event profiles do.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206 · cited 3×
“This method assesses the RBs of two treatments when they have not been compared directly with each other, but have each been compared with other treatments (Lumley, 2002).”
MethodInfluentialStein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 1×
“We abstracted data for several psychiatric rating scales including the Liebowitz Social Anxiety Scale (LSAS) (Liebowitz, 1987), the Sheehan Disability Scale (SDS) (Leon et al., 1997), and the Clinical Global Impression of Improvement Scale (CGI-I) (Guy, 1976).”
MethodPsychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396 · cited 1×
“Previous reviews have qualitatively and quantitatively summarized the response rates for select SSRIs and other older agents (Gould et al., 1997; Van der Linden et al., 2000; Fedoroff and Taylor, 2001; Blanco et al., 2003; Stein et al., 2004; Hedges et al., 2007).”
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · cited 4×
“…1999; Baldwin et al., 1999; Blomhoff et al., 2001; Van Ameringen et al., 2001; Kobak et al., 2002; Liebowitz et al., 2003; Davidson et al., 2004; Lepola et al., 2004; Rickels et al., 2004; Wagner et al., 2004; Westenberg et al., 2004; Kasper et al., 2005) were included (see Appendix 1).”
BackgroundInfluentialLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 15×
“Although patients treated with the highest dose of escitalopram (20 mg/day) had statistically significantly greater improvements in LSAS total scores than paroxetine-treated patients (20 mg/day) in an observed cases analysis, these results were not statistically significant in the ITT analysis (Lader et al., 2004).”
BackgroundResultInfluentialvan der Linden, G. J., Stein, D. J., & van Balkom, A. J. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00004 · Cited by 130
Cited by
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
“A systematic review and metaanalysis (Hansen et al., 2008) found no differences in two studies of venlafaxine versus paroxetine or in one study comparing paroxetine against citalopram.”
ResultGartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
Self-citationWilliams, T., McCaul, M., Schwarzer, G., Cipriani, A., Stein, D. J., & Ipser, J. (2020) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.6 · Cited by 59
“…2003; Van der Linden et al., 2000), aside from documented differences in the incidence of specific adverse events, existing evidence for a NMA does not suggest differences in the effectiveness of this drug(s) (Blanco et al., 2003; Hansen et al., 2008; Liu et al., 2018; Mayo-Wilson et al., 2014).”
Backgroundde Vries, Y. A., de Jonge, P., van den Heuvel, E., Turner, E. H., & Roest, A. M. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.173450 · Cited by 50
Metadata
- Authors
- Hansen, R. A., Gaynes, B. N., Gartlehner, G., Moore, C. G., Tiwari, R., & Lohr, K. N.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-05
- Volume
- 23
- Issue
- 3
- Pages
- 170-179
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2062938921
- Cited by
- 35
- References
- 9
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e3282f4224a
- The paper
- Hansen, R. A., Gaynes, B. N., Gartlehner, G., Moore, C. G., Tiwari, R., & Lohr, K. N. (2008). Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e3282f4224a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.